Why XENE fell 26.8% on Sep 18 2026: clinical trial pause
XENE-26.8%on Fri Sep 18 2026
Xenon Pharmaceuticals Inc was down 26.8% on the day at $42.00, ranked #3 on 192× its usual five-minute volume, when TapeRank recorded this drop at 06:41 ET during the pre-market session.
WHAT THE ROW LOOKED LIKE
LAST42.00
DAY▼ 26.8%
5 MIN▼ 0.31%
5M RVOL192×
5M $VOL$1.0M
FLOAT*96.7M
RANK#3
SESSIONPRE-MARKET
* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
AI VERDICT
JUSTIFIEDCONFIDENCE5/5
XENE is down 26.8% to $42 pre-market after Xenon paused enrollment in ongoing depression studies following neuropsychiatric adverse events. The pause directly threatens the psychiatry development timeline and materially outweighs the positive NDA and enrollment updates reported alongside it.
WHYA 26.8% selloff is proportionate to a safety-related clinical-trial enrollment pause that can delay or impair a major pipeline program.
ANALYZED 07:08 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNA
FILINGS · 24H BEFORE THE MOVE
- 02:04 ETXenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's WhyBenzinga
- THU 16:05 ETXenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain ActiveBenzinga
- THU 16:05 ETXenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027Benzinga
- THU 16:02 ETXenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDABenzinga
SESSION LEVELS AT CAPTURE
VWAP41.97
HOD42.50
LOD41.06
OR HIGH—
OR LOW—
PREV CLOSE57.35
PM HIGH42.50
PM LOW41.06
GAP▼ 26.77% (indicated)
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO